Vaibhav Rajoriya
Research Subjects
Vaibhav Rajoriya has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Ravikant Gupta
Oriental University, India
5 shared publicationsSudha Vengurlekar
University Institute of Pharmacy, Oriental University, Indore, Madhya Pradesh 453555, India
2 shared publications- Sushil Kumar Kashaw
Integrated Drug Discovery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar, MP, India
2 shared publications Vibha Rajoriya
Vedic Pharmacy College, Sagar, India
2 shared publications- Abhay Dubey
Department of Pharmaceutical Sciences, Dr. Harisingh Gour Central University, Sagar, India
1 shared publication - Ashish Jain
School of Pharmacy, Gyanveer University, Sagar, India
1 shared publication
Latest Publications
- 19 September 2025
- Published by IGI Global Scientific Publishing
- p. 345-380
Precautions in the Use of Herbal Polymers
Herbal polymers, derived from plant-based sources have become integral components in the development of advanced pharmaceutical and biomedical formulations. Their appeal lies in their biodegradability, non-toxic nature, renewability, and inherent therapeutic properties, which make them attractive alternatives to synthetic excipients. However, despite their natural origin, the assumption that herbal polymers are inherently safe is misleading and potentially hazardous. This chapter critically examines the precautionary principles necessary when incorporating herbal polymers into drug delivery systems, wound healing applications, and cosmeceutical products. Regulatory frameworks ranging from WHO guidelines to pharmacopeial standards are also discussed, with emphasis on the need for harmonization and transparency in herbal polymer governance. By integrating traditional ethnobotanical wisdom with cutting-edge scientific validation, the chapter advocates a balanced, evidence-based approach to unlocking the potential of herbal polymers without compromising patient safety.
- 19 September 2025
- Published by IGI Global Scientific Publishing
- p. 345-380
Precautions in the Use of Herbal Polymers
Herbal polymers, derived from plant-based sources have become integral components in the development of advanced pharmaceutical and biomedical formulations. Their appeal lies in their biodegradability, non-toxic nature, renewability, and inherent therapeutic properties, which make them attractive alternatives to synthetic excipients. However, despite their natural origin, the assumption that herbal polymers are inherently safe is misleading and potentially hazardous. This chapter critically examines the precautionary principles necessary when incorporating herbal polymers into drug delivery systems, wound healing applications, and cosmeceutical products. Regulatory frameworks ranging from WHO guidelines to pharmacopeial standards are also discussed, with emphasis on the need for harmonization and transparency in herbal polymer governance. By integrating traditional ethnobotanical wisdom with cutting-edge scientific validation, the chapter advocates a balanced, evidence-based approach to unlocking the potential of herbal polymers without compromising patient safety.
- 26 August 2025
- Published by Springer Nature in BioNanoScience
- Vol. 15 (3) , 1-13
Folate Functionalized Nanostructured Lipid Carriers of Paclitaxel for site specific A549 Lung Adenocarcinoma Targeting
- 26 August 2025
- Published by Springer Nature in BioNanoScience
- Vol. 15 (3) , 1-13
Folate Functionalized Nanostructured Lipid Carriers of Paclitaxel for site specific A549 Lung Adenocarcinoma Targeting
- 7 March 2025
- Published by IGI Global Scientific Publishing
- p. 87-106
Terpenes and Lung Cancer
Terpenoids, a broad category of secondary metabolites found in plants, have been recognized for their antioxidant, anti-inflammatory, and anticancer characteristics. These substances, which encompass monoterpenes to poly-terpenes, have been observed to impact various phases of tumor development, from the early onset and progression of tumorigenesis to the later stages of angiogenesis, invasion, and metastasis. With respect to lung cancer, a number of terpenoids have demonstrated potential effectiveness. Monoterpenes, for instance, have been associated with the prevention of cancers in the breast, liver, and lungs. Additionally, cannabinoids, a subset of terpenes, have exhibited anti-tumor effects specifically targeting lung cancer. While the anticancer properties of terpenoid are promising, there is a need for more comprehensive preclinical and translational research to fully understand their potential and to develop effective therapeutic strategies. A key area of focus in this research is understanding the complex interplay between apoptosis and autophagy, which is driven by the activation or silencing of specific proteins, in the context of terpenoid induced autophagy in cancer cells. In conclusion, terpenoids present a promising path for the development of new therapies in the management and treatment of lung cancer.
- 7 March 2025
- Published by IGI Global Scientific Publishing
- p. 87-106
Terpenes and Lung Cancer
Terpenoids, a broad category of secondary metabolites found in plants, have been recognized for their antioxidant, anti-inflammatory, and anticancer characteristics. These substances, which encompass monoterpenes to poly-terpenes, have been observed to impact various phases of tumor development, from the early onset and progression of tumorigenesis to the later stages of angiogenesis, invasion, and metastasis. With respect to lung cancer, a number of terpenoids have demonstrated potential effectiveness. Monoterpenes, for instance, have been associated with the prevention of cancers in the breast, liver, and lungs. Additionally, cannabinoids, a subset of terpenes, have exhibited anti-tumor effects specifically targeting lung cancer. While the anticancer properties of terpenoid are promising, there is a need for more comprehensive preclinical and translational research to fully understand their potential and to develop effective therapeutic strategies. A key area of focus in this research is understanding the complex interplay between apoptosis and autophagy, which is driven by the activation or silencing of specific proteins, in the context of terpenoid induced autophagy in cancer cells. In conclusion, terpenoids present a promising path for the development of new therapies in the management and treatment of lung cancer.
- 31 January 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 672, 125312
Folate conjugated Nano-Lipid construct of Paclitaxel for site-specific lung squamous carcinoma targeting
- 31 January 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 672, 125312
Folate conjugated Nano-Lipid construct of Paclitaxel for site-specific lung squamous carcinoma targeting
- 15 March 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 655, 123986
Nanostructured lipid carriers (NLCs): A promising candidate for lung cancer targeting
- 15 March 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 655, 123986
Nanostructured lipid carriers (NLCs): A promising candidate for lung cancer targeting
- 1 September 2021
- Published by Bentham Science Publishers Ltd. in Current Nanomedicine
- Vol. 11 (3) , 186-199
Folate Conjugated Solid Lipid Nanoparticle: Formulation Development, Optimization, and Characterization
Objective: The current paper represents the development, optimization, and characterization of paclitaxel-loaded folate conjugated solid lipid nanoparticles (FA-SLNs). Methods: The ligand (FA-SLNs) conjugated and non-conjugated SLNs (PTX-SLNs) were prepared by hot homogenization method. Both of the formulations (FA-SLNs and PTX-SLNs) were optimized with various parameters i.e. drug loading, stirring time, stirring speed, particle size, and polydispersity index, and characterized. The in-vitro drug release study was performed in different pH environments by using the dialysis bag method. The surface morphology and particle size were determined through scanning electron micorscopy and Transmission Electron Microscopy respectively, The SLNs formulations were also evaluated for the stability study. Result: The particle size of PTX-SLNs and FA-SLNs was determined and found to be 190.1±1.9 and 231.3±2.3 nm respectively. The surface morphology of the SLNs indicates that the prepared formulations are round-shaped and show smooth surfaces. The TEM study indicated that particles were in the range of 100-300 nm. The entrapment efficiency and drug loading capacity of FA-SLNs were found to be 79.42±1.6% and 17.3±1.9%, respectively. In-vitro drug release study data, stated that the optimum drug release was found in an acidic environment at pH 4.0, that showed 94.21% drug release after 16 hours and it proves that optimized formulation FA-SLNs will gave the sustained and better release in tumor tissue that owing acidic environment because of the angiogenesis process. Conclusion: In this research paper, different formulation parameters, found to influence fabrication of drug into Solid lipid nanoparticles, were optimized for high entrapment efficiency and drug loading. The most important parameters were drug:lipid ratio, drug:polymer ratio and lipid: surfactant ratio. Higher in-vitro drug release was observed in pH 4 as compared to the pH 7.4. These result data concludes that FA-SLNs formulation was successfully prepared, optimized and characterized.
- 1 September 2021
- Published by Bentham Science Publishers Ltd. in Current Nanomedicine
- Vol. 11 (3) , 186-199
Folate Conjugated Solid Lipid Nanoparticle: Formulation Development, Optimization, and Characterization
Objective: The current paper represents the development, optimization, and characterization of paclitaxel-loaded folate conjugated solid lipid nanoparticles (FA-SLNs). Methods: The ligand (FA-SLNs) conjugated and non-conjugated SLNs (PTX-SLNs) were prepared by hot homogenization method. Both of the formulations (FA-SLNs and PTX-SLNs) were optimized with various parameters i.e. drug loading, stirring time, stirring speed, particle size, and polydispersity index, and characterized. The in-vitro drug release study was performed in different pH environments by using the dialysis bag method. The surface morphology and particle size were determined through scanning electron micorscopy and Transmission Electron Microscopy respectively, The SLNs formulations were also evaluated for the stability study. Result: The particle size of PTX-SLNs and FA-SLNs was determined and found to be 190.1±1.9 and 231.3±2.3 nm respectively. The surface morphology of the SLNs indicates that the prepared formulations are round-shaped and show smooth surfaces. The TEM study indicated that particles were in the range of 100-300 nm. The entrapment efficiency and drug loading capacity of FA-SLNs were found to be 79.42±1.6% and 17.3±1.9%, respectively. In-vitro drug release study data, stated that the optimum drug release was found in an acidic environment at pH 4.0, that showed 94.21% drug release after 16 hours and it proves that optimized formulation FA-SLNs will gave the sustained and better release in tumor tissue that owing acidic environment because of the angiogenesis process. Conclusion: In this research paper, different formulation parameters, found to influence fabrication of drug into Solid lipid nanoparticles, were optimized for high entrapment efficiency and drug loading. The most important parameters were drug:lipid ratio, drug:polymer ratio and lipid: surfactant ratio. Higher in-vitro drug release was observed in pH 4 as compared to the pH 7.4. These result data concludes that FA-SLNs formulation was successfully prepared, optimized and characterized.
- 1 July 2021
- Published by Bentham Science Publishers Ltd. in Current Nanomedicine
- Vol. 11 (2) , 127-138
Preparation and Characterization of 5-Fluorouracil Loaded Nanogels for Skin Cancer Treatments: In Vitro Drug Release, Cytotoxicity and Cellular Uptake Analysis
Objective: The present study aimed to explore the in-vitro anticancer potential of 5-fluorouracil (5-FU) loaded PLGA nanogels coated with nerolidol sesquiterpene. Methods: The emulsification-solvent evaporation technique was used for the preparation of plain PLGA nanogels (PNGs) and 5-FU loaded PLGA nanogels (FPNGs). A surface coating of Nerolidol (2%) sesquiterpene was employed to improve the penetration efficacy of the nanogels into the stratum corneum. Results: The nanogels formulation FPNGs have the size range 220±0.25% nm obtained by dynamic light scattering. The entrapment efficiency of approx ~ 42% with a sustained-release pattern for 24 h was estimated at different pH ranges. The cell uptake and localization profile were revealed by confocal microscopy analysis using the HaCaT cell line. MTT assay demonstrated the cell compatibility of nanogels, confirmed by apoptosis assay depicting the apoptotic index of 0.87. Conclusion: This study concludes that FPNGs are a promising nanogels system against skin cancer that can be used to boost the chemo-therapeutic efficiency of bioactives with sustained and controlled release at the desired site.
- 1 July 2021
- Published by Bentham Science Publishers Ltd. in Current Nanomedicine
- Vol. 11 (2) , 127-138
Preparation and Characterization of 5-Fluorouracil Loaded Nanogels for Skin Cancer Treatments: In Vitro Drug Release, Cytotoxicity and Cellular Uptake Analysis
Objective: The present study aimed to explore the in-vitro anticancer potential of 5-fluorouracil (5-FU) loaded PLGA nanogels coated with nerolidol sesquiterpene. Methods: The emulsification-solvent evaporation technique was used for the preparation of plain PLGA nanogels (PNGs) and 5-FU loaded PLGA nanogels (FPNGs). A surface coating of Nerolidol (2%) sesquiterpene was employed to improve the penetration efficacy of the nanogels into the stratum corneum. Results: The nanogels formulation FPNGs have the size range 220±0.25% nm obtained by dynamic light scattering. The entrapment efficiency of approx ~ 42% with a sustained-release pattern for 24 h was estimated at different pH ranges. The cell uptake and localization profile were revealed by confocal microscopy analysis using the HaCaT cell line. MTT assay demonstrated the cell compatibility of nanogels, confirmed by apoptosis assay depicting the apoptotic index of 0.87. Conclusion: This study concludes that FPNGs are a promising nanogels system against skin cancer that can be used to boost the chemo-therapeutic efficiency of bioactives with sustained and controlled release at the desired site.
- 4 July 2017
- Published by Taylor & Francis in Analytical Chemistry Letters
- Vol. 7 (4) , 520-530
RP-HPLC Method for the Simultaneous Estimation of Nebivolol Hydrochloride and Valsartan
A RP-HPLC method was developed and validated for concurrent estimation of nebivolol hydrochloride (NEB) and valsartan (VAL) in a combination (5 mg: 80 mg (w/w) Byvalson TM). An RP-HPLC analysis was carried on Shimadzu LC-20AT series HPLC; C-18 ODS bonded column (25 cm × 4.60 mm, 10 μl, 40°C) used as stationary phase; potassium hydrogen phosphate buffer: acetonitrile: methanol (15:50:35v/v/v) was used as mobile phase. The retention time of the NEB and VAL were 2.930 and 4.780 min, respectively; detection carried out at λmax 273 nm for both of drug (overlain spectra). Linear regression analysis shows a good linear relationship; in the concentration range of 2.5-7.5 μg/ml and 48-112 μg/ml; for NEB and VAL with r > 0.999 and 0.997 respectively. The method was statistically validated with a relative standard deviation of less than 2% indicating high degree of accuracy and precision. Hence proposed method can be successfully applied for the simultaneous estimation of Nebivolol and Valsartan in marketed formulation. This method was successfully applied for reliable quantification of NEB and VAL in commercial and routine analysis in combined dosage form.
- 4 July 2017
- Published by Taylor & Francis in Analytical Chemistry Letters
- Vol. 7 (4) , 520-530
RP-HPLC Method for the Simultaneous Estimation of Nebivolol Hydrochloride and Valsartan
A RP-HPLC method was developed and validated for concurrent estimation of nebivolol hydrochloride (NEB) and valsartan (VAL) in a combination (5 mg: 80 mg (w/w) Byvalson TM). An RP-HPLC analysis was carried on Shimadzu LC-20AT series HPLC; C-18 ODS bonded column (25 cm × 4.60 mm, 10 μl, 40°C) used as stationary phase; potassium hydrogen phosphate buffer: acetonitrile: methanol (15:50:35v/v/v) was used as mobile phase. The retention time of the NEB and VAL were 2.930 and 4.780 min, respectively; detection carried out at λmax 273 nm for both of drug (overlain spectra). Linear regression analysis shows a good linear relationship; in the concentration range of 2.5-7.5 μg/ml and 48-112 μg/ml; for NEB and VAL with r > 0.999 and 0.997 respectively. The method was statistically validated with a relative standard deviation of less than 2% indicating high degree of accuracy and precision. Hence proposed method can be successfully applied for the simultaneous estimation of Nebivolol and Valsartan in marketed formulation. This method was successfully applied for reliable quantification of NEB and VAL in commercial and routine analysis in combined dosage form.
- 4 December 2013
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 16 (1) , 1-14
Lactosaminated-N-succinyl chitosan nanoparticles for hepatocyte-targeted delivery of acyclovir
- 4 December 2013
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 16 (1) , 1-14
Lactosaminated-N-succinyl chitosan nanoparticles for hepatocyte-targeted delivery of acyclovir